New! Sign up for our free email newsletter.
Science News
from research organizations

Combination treatment for common glioma type shows promise in mice

Preclinical study suggests new approach to treat a type of brain tumor

Date:
February 16, 2021
Source:
NIH/National Institute of Neurological Disorders and Stroke
Summary:
Gliomas are common brain tumors that comprise about one third of all cancers of the nervous system. Researchers tested a novel combination treatment approach on mice with tumors with characteristics similar to human astrocytomas and found tumor regression in 60 percent of the mice treated. These encouraging results could be the first step toward developing a treatment for this type of brain cancer.
Share:
FULL STORY

Gliomas are common brain tumors that comprise about one third of all cancers of the nervous system. In a study funded by the National Institutes of Health (NIH), researchers tested a novel combination treatment approach on mice with tumors with characteristics similar to human astrocytomas -- a type of slow-growing glioma -- and found tumor regression in 60 percent of the mice treated. These encouraging results, published in the Journal of Clinical Investigation, could be the first step toward developing a treatment for this type of brain cancer.

Led by senior authors Maria Castro, Ph.D. and Pedro Lowenstein, M.D., Ph.D. along with a team of researchers at the University of Michigan Rogel Cancer Centerb in Ann Arbor specifically tested inhibitors of the compound D-2-Hydroxyglutarate (D-2-HG), which is produced by cancer cells, on a mouse version of astrocytoma carrying mutations in the genes IDH1 and ATRX, along with an inactivated form of the tumor suppressor protein 53 (TP53) gene.

When the implanted mice were treated with a drug to block the production of D-2-HG along with standard of care radiation and temozolomide (chemotherapy) treatments, their survival significantly improved. Looking more closely at tumor cells grown in dishes, the researchers saw that blocking D-2-HG caused the cells to become more susceptible to radiation treatment. However, the treatment also increased the amount of an "immune checkpoint" protein, which tumors use to turn off T cells and evade the immune system.

Inhibiting this immune checkpoint protein with an additional drug resulted in an even greater improvement in survival, because the mouse's own immune system was able to attack the tumor.

Importantly, this combination therapy also led to immunological memory against the glioma, meaning that the mouse now had T cells tailored to the specific tumor. Because gliomas almost always grow back after treatment, these T cells make the animal better prepared to fend off regrowth.

It must be emphasized that these experiments were performed in mice. Nonetheless the preclinical results produced by this combination therapy could represent a key advance in developing an improved treatment regimen, which combines D-2-HG and immune checkpoint inhibition, radiation, and temozolomide, for patients with astrocytomas.


Story Source:

Materials provided by NIH/National Institute of Neurological Disorders and Stroke. Note: Content may be edited for style and length.


Journal Reference:

  1. Padma Kadiyala, Stephen V. Carney, Jessica C. Gauss, Maria B. Garcia-Fabiani, Santiago Haase, Mahmoud S. Alghamri, Felipe J. Núñez, Yayuan Liu, Minzhi Yu, Ayman Taher, Fernando M. Nunez, Dan Li, Marta B. Edwards, Celina G. Kleer, Henry Appelman, Yilun Sun, Lili Zhao, James J. Moon, Anna Schwendeman, Pedro R. Lowenstein, Maria G. Castro. Inhibition of 2-hydroxyglutarate elicits metabolic reprogramming and mutant IDH1 glioma immunity in mice. Journal of Clinical Investigation, 2021; 131 (4) DOI: 10.1172/JCI139542

Cite This Page:

NIH/National Institute of Neurological Disorders and Stroke. "Combination treatment for common glioma type shows promise in mice." ScienceDaily. ScienceDaily, 16 February 2021. <www.sciencedaily.com/releases/2021/02/210216185900.htm>.
NIH/National Institute of Neurological Disorders and Stroke. (2021, February 16). Combination treatment for common glioma type shows promise in mice. ScienceDaily. Retrieved December 21, 2024 from www.sciencedaily.com/releases/2021/02/210216185900.htm
NIH/National Institute of Neurological Disorders and Stroke. "Combination treatment for common glioma type shows promise in mice." ScienceDaily. www.sciencedaily.com/releases/2021/02/210216185900.htm (accessed December 21, 2024).

Explore More

from ScienceDaily

RELATED STORIES